

12 ottobre 2020

Gli studi interventistici per l'emergenza Covid-19



La situazione in Italia




* Variazione rispetto al precedente aggiornamento (14 settembre 2020)

** Di cui 2309 in studi riportati soltanto su www.clinicaltrials.gov (Dato disponibile per 60 studi)


Tipologia di intervento

Studi per categoria terapeutica




Caratteristiche degli studi


Randomizzazione




Blinding



Disegno




(Dato disponibile per 63 studi)



(Dato disponibile per 62 studi)

Fase



(Dato disponibile per 59 studi)

Numero di partecipanti

Trattamento	Fase I	Fase II	Fase II/III	Fase III	No. studi
ABX464			1034		1
Acalabrutinib		140			1
Baricitinib		139	12	400	4
Bevacizumab		27			1
Canakinumab				450	1
Colchicina		618		438	3
DAS181			nr		1
Defibrotide		50			1
Emapalumab; Anakinra			54		1
Enoxaparina		100		3312	4
Favipiravir				256	1
GRAd-COV2	90				1
Idrossiclorochina		2000		1216	4(1 nr [§])
Idrossiclorochina+Azitromicina				144	1
Immunoglobuline polivalenti		30			1
Interferone beta-1a		126			1
Ivermectina		129			1
Mavrilimumab		50			1
Multi arm 1‡				305	1
Multi arm 2‡				210	1
Multi arm 3‡				nr	1
Multi arm 4‡				350	1
Nafamostat Mesilato			256		1
Opaganib			270		1
Ossitocina		145			1
Pamrevlumab			68		1
Plasma convalescenti		327	582		8(3 na ^{§§})
Prasugrel cloridrato				128	1
Remdesivir			52	1000	3
Reparixin			159		1
Ruxolitinib				402	1
Sarilumab		40	nr	171	3
Selinexor		230			1
Sitagliptin				170	1
Tirofiban		5			1
Tocilizumab		836		330	4
Tofacitinib		166			2
Vitamina C					1(1 na ^{§§§})

§ Cumulato su 2 o più studi

na – fase non applicabile

nr – dato/fase non riportata

Numero dei partecipanti: § non riportato, §§ 69, §§§ 500

‡Multi arm 1: Darunavir/ Cobicistat; Idrossiclorochina; Lopinavir/ Ritonavir; Favipiravir;

Multi arm 2: Enoxaparina + Metilprednisolone; Eparina + Metilprednisolone;

Multi arm 3: Remdesivir; Clorochina difosfato; Idrossiclorochina solfato; Lopinavir/Ritonavir; Interferone beta-1a;


Multi arm 4: Tocilizumab; Sarilumab; Siltuximab; Canakinumab; Baricitinib; Metilprednisolone

Studi di Fase III (n=21): Randomizzati 100%; Mascherati 33%


La situazione nel mondo

1972 (+136)***

Studi nel mondo
su clinicaltrials.gov




Status




Caratteristiche degli studi


Fase




Randomizzazione



Blinding



Disegno



Focus vaccini

Fase attuale di sviluppo

75 (+17)***


Studi sui vaccini

77%
Studi
randomizzati


309370
Partecipanti

(Dato disponibile per 75 studi)

Piattaforma utilizzata per lo sviluppo dei vaccini




Fase



(Dato disponibile per 58 studi)

Numero di studi per Paese



***Variazione rispetto al precedente aggiornamento (14 settembre 2020)

Vaccino	Fase I	Fase II	Fase III
Anhui Zhifei Longcom Biologic Pharmacy	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Arcturus Therapeutics, Inc.	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Beijing Minhai Biotechnology Co. Ktd	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Beijing WANTAI Biological Pharmacy Enterprise Co.,Ltd.	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Bharat Biotech International Limited	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Biontech SE/Pfizer	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Cadila Healthcare Ltd	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
CanSino Biologics Inc.	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Chinese Academy of Medical Sciences	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Clover Biopharmaceuticals	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
CureVac AG	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Federal Budgetary Res Institution State Res Center of Virology and Biotechnology "Vector"	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Gamaleya Research Institute	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Genexine	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Henan Provincial Center	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Imperial College London	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Inovio Pharmaceuticals	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Institut Pasteur Themis Bioscience GmbH	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Coalition for Epidemic Preparedness Innovations (CEPI)	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Instituto Finlay de Vacunas	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Janssen Vaccines & Prevention B.V.	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Jiangsu Provincial Center	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Kentucky BioProcessing, Inc.	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Medicago	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Medigen Vaccine Biologics Corp.	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
ModernaTX, Inc. /NIAID	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Novavax	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Osaka University/ AnGes/ Takara Bio	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
ReiThera Srl	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Research Institute for Biological Safety Problems - Republic of Kazakhstan	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Sanofi Pasteur/GSK	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Sinovac Research	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
SpyBiothec/Serum Institute of India	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
United Biomedical Inc., Asia - COVAXX	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Universität Sklinikum Hamburg-Eppendorf	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
German Center for Infection Research	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Philipps University Marburg Medical Center	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Ludwig-Maximilians - University of Munich	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
University Hospital Tuebingen	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
University of Oxford/AstraZeneca	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
University of Queensland	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Vaxart	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
Vaxine Pty Ltd	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶
West China Hospital, Sichuan University	▶▶▶▶▶	▶▶▶▶▶	▶▶▶▶▶